Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 96Rectal Neoplasms 45Colorectal Neoplasms 45Carcinoma, Non-Small-Cell Lung 31Esophageal Neoplasms 28Esophageal Squamous Cell Carcinoma 24Stomach Neoplasms 22Lung Neoplasms 20Pancreatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Colonic Neoplasms 18Neoplasms 16Sarcoma 15Adenocarcinoma Of Esophagus 15Ovarian Neoplasms 14Neoplasm Metastasis 14Head and Neck Neoplasms 14Carcinoma, Hepatocellular 14Prostatic Neoplasms 13Urinary Bladder Neoplasms 12Uterine Cervical Neoplasms 10Inflammatory Breast Neoplasms 9Fallopian Tube Neoplasms 9Osteosarcoma 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Carcinoma, Ovarian Epithelial 7Recurrence 6Multiple Myeloma 6

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 13Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5dodecyl maltoside 5Radiotherapy 5Cystoscopy 5apaziquone 4ALT-803 4tislelizumab 35-aminolevulinic acid hexyl ester 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 2Administration, Intravesical 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔